NCT04981769 is a clinical trial of Covid-19 test in Covid19, sponsored by Anavasi Diagnostics.

Who is sponsoring NCT04981769?

NCT04981769 is sponsored by Anavasi Diagnostics.

What drugs are being tested in NCT04981769?

Interventions in NCT04981769: Covid-19 test.

Is NCT04981769 still recruiting?

NCT04981769 is currently status unknown. Last updated 29 July 2021.

Last reviewed 2021-07-29 · How we verify

NCT04981769

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

POC SARS-CoV-2 Diagnostic PCR Device Comparison to FDA Approved Reference PCR Test

Status unknown Last updated 29 July 2021

What this trial tests

trial testing Covid-19 test in Covid19 in 1,000 participants. Status unknown.

Timeline

2 August 2021

Primary endpoint
30 September 2021

30 November 2021

Quick facts

Lead sponsor	Anavasi Diagnostics
Status	Status unknown
Study type	OBSERVATIONAL
Enrollment	1,000
Start date	2 August 2021
Primary completion	30 September 2021
Estimated completion	30 November 2021

Drugs / interventions tested

Covid-19 test

Conditions studied

Covid19 — all drugs for Covid19 →

Sponsor

Anavasi Diagnostics

Who can join

Adults 2 to 125, any sex, with Covid19. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Study will assess sensitivity and specificity of AnavasiDx POC PCR device for detection of Covid-19 in patients presenting for testing a clinical sites.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other recruiting trials for Covid19

Currently open trials in the same condition.

NCT03305341 — Proof-of-Concept Clinical Pharmacology Trial for COVID-19 Antigen Presentation Therapeutic Biologic Mix · EARLY_PHASE1 · active not recruiting
NCT06482138 — Dysfunction of Olfaction After COVID-19 Infection: Morphological and Histomolecular Investigation · NA · recruiting
NCT04924803 — Community Developed Technology-Based Messaging to Increase COVID-19 Vaccine Uptake Among People Who Inject Drugs · NA · active not recruiting
NCT05013632 — COVID-19 International Drug Pregnancy Registry · recruiting
NCT04806061 — Urine Alkalinisation in COVID-19 · NA · active not recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT04981769 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Anavasi Diagnostics
Last refreshed: 29 July 2021

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04981769.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing